Register for free to
view the full innovation profile.
Opioid drug derivatives are chemically conjugated at high density on Qbeta VLPs, resulting in high titer, long-lasting antibodies after a single dose.
About
Description: Virus-like particles (VLPs) derived from Qbeta bacteriophage are engineered to allow conjugation of opioid drug derivatives. The Qbeta VLPs are highly immunogenic vaccine platforms that are multivalent, increasing the immunogenicity of molecules. The opioid drug derivatives are chemically conjugated at high density on Qbeta VLPs, resulting in high titer, long-lasting antibodies after a single dose. The anti-peptide antibodies are elicited as early as a week after immunization. Within 2 to 3 weeks, a high titer is achieved. Potential applications: Clinical applications to overcome opioid use disorder. Benefits and advantages: This vaccine is a novel treatment method for opioid dependency, overdose, and withdrawal. The vaccines could possibly prevent opioid drug from crossing the blood-brain barrier and prevent opioid-mediated antinociception. Also, the Qbeta VLPs elicit high titer and long-lasting antibodies.
Key Benefits
Benefits and advantages: This vaccine is a novel treatment method for opioid dependency, overdose, and withdrawal. The vaccines could possibly prevent opioid drug from crossing the blood-brain barrier and prevent opioid-mediated antinociception. Also, the Qbeta VLPs elicit high titer and long-lasting antibodies.
Applications
Potential applications: Clinical applications to overcome opioid use disorder.